Login to Your Account



Of ratios, ASCO pre-glow: Celator encore tells more, Vyxeos AML Trojan horse

By Randy Osborne
Staff Writer

Wednesday, May 11, 2016

Wall Street speculation that a pending ex-U.S. partnership "could lead into something greater or bigger" helped bump shares of Celator Pharmaceuticals Inc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription